Impact of platelet inhibition level on subsequent no-reflow in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction;Impact du niveau d'inhibition plaquettaire sur la survenue du no-reflow chez les patients admis pour syndrome coronaire aigu avec sus-décalage du segment ST qui vont bénéficier d'un traitement par angioplastie primaire

Archives of Cardiovascular Diseases

Volumn 110, Issue 11, 2017, Pages 626-633

  Aitmokhtar, Omar ^a,b   Paganelli, Franck ^b   Benamara, Saida ^a   Azaza, Adel ^a   Bonello, Laurent ^b   Hamza, Ouafa ^a   Seddiki, Saber ^a   Benathmane, Tayeb ^b   Saidane, Mourad ^a   Bouzid, Ahmed ^a   Kara, Maamar ^a   Sik, Arezki ^a   Azzouz, Abdelmalek ^a   Harbi, Faiza ^a   Monsuez, Jean Jacques ^b   Benkhedda, Salim ^a,b  

^a CHU Mustapha   (Algeria)

^b HÔPITAL NORD   (France)

Author keywords

No reflow; Platelet reactivity; Primary PCI; ST segment resolution

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ANTITHROMBOCYTIC AGENT; P2RY12 PROTEIN, HUMAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; PURINERGIC P2Y12 RECEPTOR; TICLOPIDINE;

ADULT; ARTICLE; CORONARY ARTERY DILATATION; FEMALE; HEART MUSCLE REVASCULARIZATION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; MIDDLE AGED; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PROSPECTIVE STUDY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THERAPY DELAY; AGED; ANALOGS AND DERIVATIVES; AREA UNDER THE CURVE; BLOOD; BLOOD CLOTTING PARAMETERS; CHI SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY BLOOD FLOW; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG RESISTANCE; METABOLISM; MICROCIRCULATION; MULTIVARIATE ANALYSIS; NO REFLOW PHENOMENON; ODDS RATIO; PATHOPHYSIOLOGY; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; THROMBOCYTE; TIME FACTOR; TREATMENT OUTCOME;

AGED; AREA UNDER CURVE; ASPIRIN; BLOOD PLATELETS; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY CIRCULATION; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; NO-REFLOW PHENOMENON; ODDS RATIO; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P2Y12; RISK FACTORS; ROC CURVE; ST ELEVATION MYOCARDIAL INFARCTION; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85020083799     PISSN: 18752136     EISSN: 18752128     Source Type: Journal    
DOI: 10.1016/j.acvd.2016.12.017     Document Type: Article

References (29)

1. Gawaz, M., Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res 61 (2004), 498–511.
2. Ruggeri, Z.M., Platelets in atherothrombosis. Nat Med 8 (2002), 1227–1234.
3. Aradi, D., Tornyos, A., Pinter, T., et al. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. J Am Coll Cardiol 63 (2014), 1061–1070.
4. Sibbing, D., Bernlochner, I., Schulz, S., et al. Prognostic value of a high on-clopidogrel treatment platelet reactivity in bivalirudin versus abciximab treated non-ST-segment elevation myocardial infarction patients. ISAR-REACT 4 (intracoronary stenting and antithrombotic regimen: rapid early action for coronary treatment-4) platelet substudy. J Am Coll Cardiol 60 (2012), 369–377.
5. Frossard, M., Fuchs, I., Leitner, J.M., et al. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 110 (2004), 1392–1397.
6. Choudhri, T.F., Hoh, B.L., Zerwes, H.G., et al. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation. J Clin Invest 102 (1998), 1301–1310.
7. Kupatt, C., Habazett, H., Hanusch, P., et al. c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury. Arterioscler Thromb Vasc Biol 20 (2000), 2226–2232.
8. Heestermans, A.A., van Werkum, J.W., Taubert, D., et al. Impaired bioavailability of clopidogrel in patients with a ST-segment elevation myocardial infarction. Thromb Res 122 (2008), 776–781.
9. Valgimigli, M., Tebaldi, M., Campo, G., et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (facilitation through aggrastat by dropping or shortening infusion line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 5 (2012), 268–277.
10. Montalescot, G., Bolognese, L., Dudek, D., et al. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 369 (2013), 999–1010.
11. Montalescot, G., van't Hof, A.W., Lapostolle, F., et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371 (2014), 1016–1027.
12. Alexopoulos, D., Bhatt, D.L., Hamm, C.W., Steg, P.G., Stone, G.W., Early P2Y12 inhibition in ST-segment elevation myocardial infarction: bridging the gap. Am Heart J 170 (2015), 3–12.
13. Steg, P.G., James, S.K., Atar, D., et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 33 (2012), 2569–2619.
14. Bonello, L., Pansieri, M., Mancini, J., et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. J Am Coll Cardiol 58 (2011), 467–473.
15. Alexopoulos, D., Theodoropoulos, K.C., Stavrou, E.F., et al. Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction. Cardiovasc Drugs Ther 26 (2012), 393–400.
16. Alexopoulos, D., Xanthopoulou, I., Gkizas, V., et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 5 (2012), 797–804.
17. Bozbeyoglu, E., Satilmis, S., Aksu, H., Yildirimturk, O., Nurkalem, Z., Impact of clopidogrel resistance on ST-segment resolution and no-reflow in acute myocardial infarction with ST-elevation patients treated with a primary percutaneous coronary intervention. Coron Artery Dis 23 (2012), 523–527.
18. Parodi, G., Valenti, R., Bellandi, B., et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study. J Am Coll Cardiol 61 (2013), 1601–1606.
19. Bouleti, C., Mewton, N., Germain, S., The no-reflow phenomenon: state of the art. Arch Cardiovasc Dis 108 (2015), 661–674.
20. Monassier, J.P., Reperfusion injury in acute myocardial infarction: from bench to cath lab. Part II: clinical issues and therapeutic options. Arch Cardiovasc Dis 101 (2008), 565–575.
21. Ait-Mokhtar, O., Bonello, L., Benamara, S., Paganelli, F., High on treatment platelet reactivity. Heart Lung Circ 21 (2012), 12–21.
22. Campo, G., Valgimigli, M., Gemmati, D., et al. Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol 48 (2006), 2178–2185.
23. Mangiacapra, F., Muller, O., Ntalianis, A., et al. Comparison of 600 versus 300-mg clopidogrel-loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol 106 (2010), 1208–1211.
24. Beigel, R., Fefer, P., Rosenberg, N., et al. Antiplatelet effect of thienopyridine (clopidogrel or prasugrel) pretreatment in patients undergoing primary percutaneous intervention for ST elevation myocardial infarction. Am J Cardiol 112 (2013), 1551–1556.
25. Wallentin, L., Varenhorst, C., James, S., et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J 29 (2008), 21–30.
26. de Lemos, J.A., Braunwald, E., ST-segment resolution as a tool for assessing the efficacy of reperfusion therapy. J Am Coll Cardiol 38 (2001), 1283–1294.
27. Matetzky, S., Novikov, M., Gruberg, L., et al. The significance of persistent ST elevation versus early resolution of ST-segment elevation after primary PTCA. J Am Coll Cardiol 34 (1999), 1932–1938.
28. Schroder, R., Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation 110 (2004), e506–e510.
29. Hanssen, M., Cottin, Y., Khalife, K., et al. French Registry on Acute ST-elevation and non ST-elevation myocardial infarction 2010. FAST-MI 2010. Heart 98 (2012), 699–705.